PSG1

Across TCGA pan-cancer cohorts, PSG1 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated PSG1 data layer compared with 5 for mutation status.

The strongest signal is observed in mesothelioma (MESO), where higher PSG1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PSG1 expression acts as an unfavorable survival marker, although some lineages such as THCA and PAAD show a favorable association.

MESO, KIRC, and COAD are the cancer types where PSG1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	All	0.359	0.616	<.001	156	view →
KIRC	DFS	Tertile	All	0.528	0.699	<.001	76	view →
COAD	DFS	Tertile	III,IV	0.192	0.653	<.001	51	view →
DLBC	OS	Median	III,IV	0.310	1.000	.011	43	view →
SCLC	OS	Tertile	II,III,IV	0.164	0.819	<.001	36	view →
THCA	OS	Median	All	1.000	0.962	.009	30	view →
LUSC	OS	Quartile	III,IV	0.307	0.630	<.001	25	view →
LIHC	OS	Tertile	All	0.576	0.705	.022	21	view →
TGCT	DFS	Tertile	III,IV	0.505	1.000	.031	20	view →
SKCM	OS	Tertile	IV	0.184	0.779	<.001	19	view →
LGG	DFS	Quartile	All	0.720	0.858	.001	18	view →
UCS	OS	Quartile	III,IV	0.194	0.583	.001	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

PSG1–MESO (OS)

Open the MESO breakdown →